Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts

Neoplasia

Volumn 10, Issue 4, 2008, Pages 303-313

  Chung, Yuen Li ^a,c   Troy, Helen ^a   Kristeleit, Rebecca ^b   Aherne, Wynne ^b   Jackson, L Elizabeth ^c   Atadja, Peter ^d   Griffiths, John R ^a,e   Judson, Ian R ^b   Workman, Paul ^b   Leach, Martin O ^c   Beloueche Babari, Mounia ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; CD31 ANTIGEN; ESTER; HISTONE DEACETYLASE INHIBITOR; PHOSPHOMONOESTER; PHOSPHORUS; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CELL PH; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; STAINING; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 41649085784     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07834     Document Type: Article

References (58)

1. Legube G and Trouche D (2003). Regulating histone acetyltransferases and deacetylases. EMBO Rep 4, 944-947.
2. Struhl K (1998). Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12, 599-606.
3. Sengupta N and Seto E (2004). Regulation of histone deacetylase activities. J Cell Biochem 93, 57-67.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, and Kelly WK (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1, 194-202.
5. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, and Dammann R (2002). Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62, 3698-3701.
6. van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruïne AP, Arends JW, van den Brandt PA, de Goeij AF, and Herman JG (2002). K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21, 3792-3795.
7. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7, 437-443.
8. Kristeleit R, Stimson L, Workman P, and Aherne W (2004). Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 9, 135-154.
9. Marks PA, Richon VM, and Rifkind PA (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92, 1210-1216.
10. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, and Ilstrup SJ (2005). Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 4, 603-611.
11. Maeda T, Nagaoka Y, Kawai Y, Takagaki N, Yasuda C, Yogosawa S, Sowa Y, Sakai T, and Uesato S (2005). Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G(2)/M arrest. Biol Pharm Bull 28, 849-853.
12. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, and Kim KW (2002). Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-720.
13. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, and Pili R (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res 66, 8814-8821.
14. Mie LY, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, and Kim KW (2003). Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 300, 241-246.
15. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, Lee HY, Lee YW, et al. (2000). Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60, 6068-6074.
16. Deroanne CF, Bonjean K, Serotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427-436.
17. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Förstermann U, Zeiher AM, and Dimmeler S (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91, 837-844.
18. Scott GK, Marden C, Xu F, Kirk L, and Benz CC (2002). Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1, 385-392.
19. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, and Benz CC (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45, 495-528.
20. McCabe MT, Azih OJ, and Day ML (2005). pRb-independent growth arrest and transcriptional regulation of E2F target genes. Neoplasia 7, 141-151.
21. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280, 26729-26734.
22. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, and Wu J (2005). Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4, 1311-1319.
23. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, et al. (2003). Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63, 5126-5135.
24. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, et al. (2004). Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64, 689-695.
25. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, and Pili R (2004). The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor reception tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64, 6626-6634.
26. 18F] fluorothymidine positron emission tomography. Cancer Res 66, 7621-7629.
27. Workman P, Aboagye EO, Chung Y-L, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, and Zweit J (2006). Minimally-invasive pharmacokinetic and pharmacodynamic technologies in hypothesis - testing clinical trials of innovative therapies. J Natl Cancer Inst 98, 580-598.
28. Workman P (2002). Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38, 2189-2193.
29. Workman P (2003). How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9, 891-902.
30. Parulekar WR and Eisenhauer EA (2004). Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96, 990-997.
31. Webb GA, Ed (2006). Modern Magnetic Resonance. Part II: Applications in Medical and Pharmaceutical Sciences. New York, Springer.
32. 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institution trial. NMR Biomed 19, 504-512.
33. Galbraith SM (2006). MR in oncology drug development. NMR Biomed 19, 681-689.
34. 31P measurements of response to treatment. NMR Biomed 11, 314-340.
35. 31P magnetic resonance spectroscopy study. Radiat Oncol Investig 6, 249-254.
36. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, et al. (2003). Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 95, 1624-1633.
37. Al-Saffar NMS, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, et al. (2006). Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 66, 427-434.
38. Beloueche-Babari M, Jackson LE, Al-Saffar NMS, Workman P, Leach MO, and Ronen SM (2005). Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 65, 3356-3363.
39. Glunde K and Serkova NJ (2006). Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7, 1109-1123.
40. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, and Richon VM (2001). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61, 8492-8497.
41. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82, 1107-1112.
42. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al. (1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77, 1-10.
43. Tyagi RK, Azrad A, Degani H, and Salomon Y (1996). Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 35, 194-200.
44. Ordidge RJ, Connelly A, and Lohman JAB (1986). Image selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 66, 283-294.
45. 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 6, 92-98.
46. Bergmeyer HU (1974). Methods of Enzymatic Analysis. Weinheim, Germany: Verlag Chemie.
47. Sitter B, Sonnewald U, Spraul M, Fjosne HE, and Gribbestad IS (2000). High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 15, 327-337.
48. Sankaranarayanapillai M, Tong WP, Maxwell DA, Pal A, Pang J, Bornmann WG, Gelovani JG, and Ronen SM (2006). Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 5, 1325-1334.
49. Clark PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, and Workman P (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allyamino,17- demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 19, 4125-4133.
50. Negendank WG (1992). Studies of human tumors by MRS: a review. NMR Biomed 5, 303-324.
51. 1H MRS markers of tumor growth in intrasplenic tumors and liver metastasis induced by injection of HT-29 cells in nude mice spleen. NMR Biomed 11, 93-106.
52. Negendank WG, Padavic-Shaller KA, Li C-W, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, and Brown TR (1995). Metabolic characterisation of non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 55, 3286-3294.
53. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, and Delikatny EJ (2005). Increases in NMR-visible lipid and glycerol-phosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta 1734, 1-12.
54. MacPhail LB, Chung Y-L, Madhu B, Clark S, Griffiths SR, Kelland LR, and Robinson SP (2005). An investigation of tumor dose response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11, 3705-3713.
55. 1H magnetic resonance spectroscopy. Neoplasia 8, 560-567.
56. Weinberg RA (2007). The Biology of Cancer New York, Garland, 580.
57. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors: review. Cancer Res 49, 6449-6465.
58. Jain RK and Carmeliet PF (2001). Vessels of death or life. Sci Am 285, 38-45.